BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32473643)

  • 21. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
    Conte B; Bruzzone M; Lambertini M; Poggio F; Bighin C; Blondeaux E; De Laurentiis M; Valle E; Cognetti F; Nisticò C; De Placido S; Garrone O; Gamucci T; Montemurro F; Puglisi F; Cardinali B; Fregatti P; Miglietta L; Boccardo F; Ceppi M; Del Mastro L;
    Eur J Cancer; 2020 Sep; 136():43-51. PubMed ID: 32634760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure.
    Moran MS; Haffty BG
    Breast J; 2002; 8(2):81-7. PubMed ID: 11896752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of relapse in breast cancer: changes over time.
    Yerushalmi R; Woods R; Kennecke H; Speers C; Knowling M; Gelmon K
    Breast Cancer Res Treat; 2010 Apr; 120(3):753-9. PubMed ID: 19701704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy.
    Wickberg Å; Magnuson A; Holmberg L; Adami HO; Liljegren G
    Breast; 2018 Dec; 42():54-60. PubMed ID: 30176553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic escalation - De-escalation: Data from 15.508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SLNB).
    Houvenaeghel G; Lambaudie E; Cohen M; Classe JM; Reyal F; Garbay JR; Giard S; Chopin N; Martinez A; Rouzier R; Daraï E; Colombo PE; Coutant C; Gimbergues P; Azuar P; Villet R; Tunon de Lara C; Barranger E; Sabiani L; Goncalves A
    Breast; 2017 Aug; 34():24-33. PubMed ID: 28475932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    Sun Y; Wu X; Zhang Y; Lin H; Lu X; Huang Y; Chi P
    Eur J Surg Oncol; 2019 Jul; 45(7):1225-1231. PubMed ID: 30879932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
    Faradmal J; Kazemnejad A; Khodabakhshi R; Gohari MR; Hajizadeh E
    Asian Pac J Cancer Prev; 2010; 11(2):353-8. PubMed ID: 20843115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pattern of distant metastasis in molecular subtypes of carcinoma breast: An institutional study.
    Kunikullaya SU; Poddar J; Sharma AD; Patel S
    Indian J Cancer; 2017; 54(1):327-332. PubMed ID: 29199716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
    Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
    J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N; Mukai H; Fujii S; Wada N
    Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
    Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer.
    De Iuliis F; Salerno G; Corvino R; D'Aniello D; Cefalì K; Taglieri L; Lanza R; Scarpa S
    Clin Breast Cancer; 2017 Feb; 17(1):34-40. PubMed ID: 27435626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center.
    Khallaf SM; Roshdy J; Ibrahim A
    J Egypt Natl Canc Inst; 2020 Apr; 32(1):20. PubMed ID: 32372114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.